Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations

Name: Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations
License: Public Domain

National Cancer Institute (NCI)

ClinicalTrials.gov · Datasets · License: Public Domain

Open Source ↗

anatomic stage iv breast cancer ajcc v8, castration-resistant prostate carcinoma, stage ivb prostate cancer ajcc v8

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 387171
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.